CN114908004A - Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof - Google Patents
Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof Download PDFInfo
- Publication number
- CN114908004A CN114908004A CN202210433128.1A CN202210433128A CN114908004A CN 114908004 A CN114908004 A CN 114908004A CN 202210433128 A CN202210433128 A CN 202210433128A CN 114908004 A CN114908004 A CN 114908004A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium infantis
- atopic dermatitis
- rego
- mice
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 title claims abstract description 92
- 229940004120 bifidobacterium infantis Drugs 0.000 title claims abstract description 91
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 57
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 16
- 238000004321 preservation Methods 0.000 claims abstract description 9
- 238000011282 treatment Methods 0.000 claims description 20
- 230000001580 bacterial effect Effects 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000013365 dairy product Nutrition 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000013622 meat product Nutrition 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 22
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 229960001340 histamine Drugs 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 210000002966 serum Anatomy 0.000 abstract description 8
- 208000003251 Pruritus Diseases 0.000 abstract description 7
- 210000003630 histaminocyte Anatomy 0.000 abstract description 6
- 239000000654 additive Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 52
- 239000000243 solution Substances 0.000 description 23
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 239000001963 growth medium Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 102000003816 Interleukin-13 Human genes 0.000 description 9
- 108090000176 Interleukin-13 Proteins 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 9
- 108090000978 Interleukin-4 Proteins 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 229940028885 interleukin-4 Drugs 0.000 description 7
- 238000000465 moulding Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000021107 fermented food Nutrition 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- 244000144730 Amygdalus persica Species 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 2
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940046731 calcineurin inhibitors Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C13/00—Cream; Cream preparations; Making thereof
- A23C13/12—Cream preparations
- A23C13/16—Cream preparations containing, or treated with, microorganisms, enzymes, or antibiotics; Sour cream
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/60—Drinks from legumes, e.g. lupine drinks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof, wherein the bifidobacterium infantis is identified as bifidobacterium infantis (Bifidobacterium infantis)Bifidobacterium infantis) The strain is named as REGO and is preserved in China center for type culture Collection with the preservation date of 2021, 03 and 24 days and the preservation number of CCTCC No. M2021268. The bifidobacterium infantis provided by the invention has good growth characteristics, can improve the swelling degree of atopic dermatitis, reduce the total IgE level in serum and the degranulation phenomenon of mast cells, recover the immune balance between Th1/Th2 in local tissues, remarkably reduce the release of histamine in the local tissues, and relieve the skin pruritus symptom, thereby relieving the inflammation of the atopic dermatitis; the product is prepared into a corresponding product for relieving atopic dermatitis, and can remarkably relieve symptoms and inhibit inflammation; therefore, the bifidobacterium infantis can be used for preparing medicines, functional foods and food/medicine additive components capable of preventing and/or treating atopic dermatitis, and has high application value.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof.
Background
Atopic Dermatitis (AD) is a chronic, recurrent, inflammatory skin disease that is often accompanied by severe itching and other allergic diseases. Meanwhile, AD is a common non-infectious skin disease affecting up to 20% of children and 2-8% of adults in most countries worldwide, and its clinical manifestations are diversified and can be divided into infancy, childhood, and adolescence according to its occurrence, development and distribution characteristics
The three stages of juvenile and adult, wherein most of AD patients occur in infancy, and serious patients can even continue to adult, which is one of worldwide public health problems due to the repeated serious influence on the life quality of the patients, and therefore needs to be paid more attention.
The manifestations of AD, similar to asthma and allergic rhinitis, are mainly associated with local infiltration of T lymphocytes secreting interleukin-4 (IL-4), interleukin-13 (IL-13), etc., whereas IL-4, IL-13, associated with the development of a phenotype that regulates helper T cell 2(Th2), results in immunoglobulin (Ig) overproduction and eosinophilia; also, elevated levels of total IgE and allergen-specific IgE are a characteristic feature of AD, which is shared by at least 50% of AD patients, and this IgE is primarily targeted to environmental allergens. Therefore, there are several abnormal immune response steps in the development and progression of AD, such as: presentation of allergens by langerhans cells and skin dendritic cells, abnormal immune response mainly including Th2, regulatory T cell dysfunction, excessive IgE production, increased eosinophils, and the like.
At present, no therapeutic drug with definite curative effect for AD exists for constipation, and the adopted solution mainly relieves the symptoms of AD by external drugs such as glucocorticoid drugs, calcineurin inhibitors, external antimicrobial preparations, antihistamines, anti-inflammatory mediator drugs, immunosuppressants and the like. However, the above drugs have great adverse reactions, and most patients have concerns about hormone drugs, which not only bring great difficulty to the treatment of AD, but also bring great trouble to the lives of patients, and in addition, the drugs have poor tolerance for individual patients.
Therefore, there is still a need for a drug or a treatment that does not cause side effects to patients, can be used to combat the onset of allergy and the development of skin inflammation, relieve the symptoms of skin itch, eczema and the like in patients, and can be applied to various types of patients with good tolerance to the patients. Probiotics are active microorganisms which are beneficial to a host and change the composition of flora at a certain part of the host by colonizing in a human body. Compared with common medicines, the probiotics has the advantages of high safety, no side effect, low cost and the like. Therefore, a method of alleviating AD by using probiotics would be an important means that can be preferentially taken and has low side effects. Research on the effect of bifidobacterium infantis on AD alleviation will have great influence on food science, microbiology, preventive medicine and other aspects, so that screening bifidobacterium infantis with an effect of alleviating AD is necessary.
Disclosure of Invention
The purpose of the invention is as follows: in view of the problems of the prior art, the invention aims to provide bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof.
The technical scheme is as follows: in order to achieve the purpose of the invention, the technical scheme adopted by the invention is as follows:
bifidobacterium infantis identified as Bifidobacterium infantis (B.infantis)Bifidobacteriuminfantis) The strain is named as REGO and is preserved in China center for type culture Collection with the preservation date of 2021, 03 and 24 days, the preservation number is CCTCC No. M2021268, and the preservation address is Wuhan university in Wuhan Han China.
Bifidobacterium infantis: (Bifidobacterium infantis) The strain is derived from fresh excrement sample of healthy female infant, the 16S rDNA sequence of the strain is shown as SEQ ID NO.1 through sequencing analysis, the sequence obtained through sequencing is compared with the nucleic acid sequence in NCB, and the result shows that the strain is bifidobacterium infantis and is named as bifidobacterium infantis REGO (R) (C)Bifidobacterium infantisREGO)。
Bifidobacterium infantis: (Bifidobacterium infantis) The colonies on MRS medium are convex to pad, complete in edge, soft, moist, white and shiny, and have the following characteristics: .
(1) Significantly improve the ear swelling degree of atopic dermatitis mice;
(2) the total IgE level in the serum of the atopic dermatitis mouse is obviously reduced by regulating the immune system of the mouse in vivo;
(3) the method is favorable for reducing the mastocyte degranulation phenomenon in a mouse body so as to obviously improve the dermatitis inflammation of the atopic dermatitis mouse;
(4) significantly reducing the level of cytokines (IL-4 and IL-13) related to Th2 cells in local tissues of mice so as to restore the immune balance between Th1/Th2 in the local tissues of atopic dermatitis mice;
(5) significantly reduces the release of histamine in local tissues of the mice, relieves the skin itch symptom of the atopic dermatitis mice, and relieves the dermatitis inflammation of the atopic dermatitis mice.
The invention also provides application of the bifidobacterium infantis in preparing medicines or foods for preventing and/or treating atopic dermatitis. Or the application of the bifidobacterium infantis in preparing medicines or foods for relieving atopic dermatitis.
Preferably, in the medicine or food, the viable count of the bifidobacterium infantis is not less than 1 x 10 6 CFU/g or 1X 10 6 CFU/mL。
Preferably, the dosage form of the medicine is powder, granules, capsules, tablets, pills or oral liquid; the food is a health food; or the food comprises dairy products, bean products, meat products or fruit and vegetable products; or the food is a beverage or snack.
The invention also provides a composition containing the bifidobacterium infantis.
Preferably, the composition comprises the bifidobacterium infantis, a pharmaceutical carrier and/or a pharmaceutical excipient.
Further preferably, the drug carrier comprises microcapsules, microspheres, nanoparticles and/or liposomes; the pharmaceutic adjuvant comprises an excipient and/or an additive.
More preferably, the excipient comprises a binder, filler, disintegrant and/or lubricant; the additive comprises a solubilizer, a cosolvent and/or a preservative.
Preferably, the composition comprises the bifidobacterium infantis and edible auxiliary materials.
As an embodiment, the composition comprises the use of a composition comprising said Bifidobacterium infantis (b: (a))Bifidobacterium infantis) The dairy product, the bean product or the fruit and vegetable product are produced by the leaven; or comprises the Bifidobacterium infantis (Bifidobacterium infantis) The solid beverage of (1).
Preferably, the preparation method of the leaven is that bifidobacterium infantis (b)Bifidobacterium infantis) Inoculating the strain into a culture medium according to the inoculum size accounting for 2-4% of the total mass of the culture medium, and culturing at 37 +/-2 ℃ for 16 +/-2 h to obtain a culture solution; centrifuging the culture solution to obtain thalli; cleaning the bacteria with phosphate buffer solution with the pH value of 7.2-7.4, and then resuspending the bacteria with a freeze-drying protective agent to obtain a resuspension solution; and (4) freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain the leavening agent.
Further preferred is:
the mass ratio of the freeze-drying protective agent to the thallus is 2: 1.
The culture medium comprises 87.5 percent of water, 12 percent of skim milk, 0.6 percent of glucose, 1.4 percent of tryptone and 0.4 percent of yeast extract solution by mass of the total mass of the culture medium.
The pH of the medium was 6.8.
The protective agent comprises 100g/L of skimmed milk powder, 150g/L of trehalose and 10g/L of L-sodium glutamate.
As another embodiment, the composition further comprises a bacterial agent obtained by drying a bacterial solution containing the bifidobacterium infantis. Further preferably, the drying adopts vacuum freeze drying or other bacteria liquid drying processes.
The invention finally provides the application of the composition in preparing a medicament or food for preventing and/or treating atopic dermatitis.
Has the advantages that: the bifidobacterium infantis provided by the invention has good growth characteristics, can improve the swelling degree of atopic dermatitis, reduce the total IgE level in serum and the degranulation phenomenon of mast cells, recover the immune balance between Th1/Th2 in local tissues, remarkably reduce the release of histamine in the local tissues, and relieve the skin pruritus symptom, thereby relieving the inflammation of the atopic dermatitis; the product is prepared into a corresponding product for relieving atopic dermatitis, and can remarkably relieve symptoms and inhibit inflammation; therefore, the bifidobacterium infantis can be used for preparing medicines, functional foods and food/medicine additive components capable of preventing and/or treating atopic dermatitis, and has high application value.
Drawings
FIG. 1: comparison of the effect of different groups on reducing the thickness of the ears in atopic dermatitis mice.
FIG. 2: comparison of the effects of different groups on reducing the serum total IgE levels of atopic dermatitis mice.
FIG. 3: comparison of the effects of different groups on the reduction of IL-4 levels in the skin tissues of atopic dermatitis mice.
FIG. 4: comparison of the effects of different groups on the reduction of IL-13 levels in the skin tissues of atopic dermatitis mice.
FIG. 5: comparison of the effects of different groups on reducing histamine levels in skin tissues of atopic dermatitis mice.
Detailed Description
The invention is further illustrated by the following examples. These examples are purely illustrative and they are intended to describe the invention in detail only and should not be interpreted as limiting the invention. The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or apparatus used are conventional products commercially available from normal sources, not indicated by the manufacturer.
The media referred to in the examples below are as follows.
MRS solid medium (g/L): 10g/L of peptone, 10g/L of beef extract, 20g/L of glucose, 2g/L of sodium acetate, 5g/L of yeast powder and 2g/L, K of diammonium hydrogen citrate 2 PO 4 ·3H 2 O 2.6g/L、MgSO 4 ·7H 2 O 0.1g/L、MnSO 4 0.05g/L, Tween 801 mL/L, agar 20g/L and cysteine hydrochloride 0.5 g/L.
MRS liquid medium (g/L): 10g/L of peptone, 10g/L of beef extract, 20g/L of glucose, 2g/L of sodium acetate, 5g/L of yeast powder and 2g/L, K of diammonium hydrogen citrate 2 PO 4 ·3H 2 O 2.6g/L、MgSO 4 ·7H 2 O.1g/L, MnSO40.05g/L, Tween 801 mL/L, cysteine hydrochloride 0.5 g/L.
Example 1: and (3) screening the bifidobacterium infantis and identifying strains.
1. Screening
Taking excrement of healthy female infants from Sagao Rugao city in Jiangsu province as a sample, pretreating the sample, storing the pretreated sample in about 20% of glycerol in a refrigerator at the temperature of-80 ℃, taking out the sample, thawing the sample, uniformly mixing the sample, sucking 0.5mL of the sample, adding the sample into 4.5mL of the sample, performing gradient dilution by using 0.9% of normal saline containing 0.05% of cysteine, selecting a proper gradient diluent to be coated on an MRS solid culture medium added with 0.05% of cysteine, culturing the sample at the temperature of 37 ℃ for 48 hours, selecting a typical colony, streaking and purifying the typical colony on the MRS solid culture medium, selecting a single colony, transferring the single colony to an MRS liquid culture medium (containing 0.05% of cysteine) for enrichment, and preserving the single colony by using 30% of glycerol to obtain a strain REGO.
2. Identification
Extracting genome of REGO, amplifying and sequencing 16S rDNA of REGO, wherein the nucleotide sequences amplified by 16S rDNA of REGO are respectively shown as SEQ ID NO.1, and the sequence is subjected to nucleic acid sequence comparison in NCBI, and the result shows that the strain is bifidobacterium infantis and named as bifidobacterium infantis REGO (REGO) ((R))Bifidobacterium infantisREGO)。
The obtained Bifidobacterium infantis is classified and named as Bifidobacterium infantis REGO (B)Bifidobacteri- um infantisREGO) The strain has been preserved in China center for type culture Collection (preservation center of Wuhan university) at 31.3.31.2021, with the preservation number of CCTCC No. M2021268 and the preservation address of No. 299 in the Wuhan City, Hubei province.
Example 2: culture of Bifidobacterium infantis
Bifidobacterium infantis (Bifidobacterium infantis) The bacterial colony is observed after the REGO is inoculated into an MRS solid culture medium (containing 0.05% cysteine) and cultured for 48 hours at 37 ℃, and the bacterial colony is found to be convex to pad-shaped, complete in edge, soft, moist, white and glossy.
Bifidobacterium infantis (Bifidobacterium infantis) Inoculating REGO into MRS liquid culture medium (containing 0.05% cysteine), anaerobically culturing at 37 deg.C for 24 hr, transferring into fresh MRS liquid culture medium (containing 0.05% cysteine), culturing under the same conditions for 24 hr, centrifuging thallus at 6000g for 15min, washing thallus with 0.9% physiological saline at 6000g, centrifuging again at 6000g for 10min to obtain thallus, and resuspending with 30% sucrose solutionAnd freezing at-80 deg.c for use. The experimental results are as follows: the initial viable count is 1 × 10 11 CFU/mL, viable count 1X 10 after 1 week 11 CFU/mL, the order of magnitude does not change, show that the bacterial liquid does not influence the experiment after being frozen, and can be used for animal experiments.
Example 3: effect of Bifidobacterium infantis on ear thickness in atopic dermatitis mice
30 healthy female C57BL/6 mice weighing 18-20g were randomly divided into 5 groups of 10 mice each, and 3 groups were: a blank group (control group), a model group administered with 2, 4-dinitrofluorobenzene (2, 4-dinitrofluorobenzene, DNFB), and a REGO group administered with Bifidobacterium infantis REGO, wherein the REGO group is a treatment group. The experiment was carried out for four weeks: the first week is the adaptation period of the mice; beginning intragastric administration in the second week until the experiment is finished, and respectively performing intragastric administration on the Bifidobacterium infantis REGO bacterial liquid in the treatment groups by 0.2mL (the total amount of viable bacteria in single intragastric administration is 1 × 10) 9 Performing gavage at the dosage of CFU)/one time, wherein the blank group and the model group are not subjected to bacterial liquid intervention, and only the same amount of physiological saline is used as a control; the third week to the fourth week are modeling periods, the model group and the right ear of the mouse in the treatment group are smeared with 50 mu L of DNFB solution with the concentration of 0.5% for skin lesion sensitization and excitation on the 1 st day of modeling, the model group and the right ear of the mouse in the treatment group are smeared with 20 mu L of DNFB solution with the concentration of 0.2% on the 5 th, 8 th, 11 th and 14 th days, and the right ear of the mouse in the blank group is smeared with the same amount of acetone/olive oil matrix solution as a control; all groups were free water and food intake.
The ear thickness of 5 groups of mice was measured by a digital display micrometer screw before the start of molding (i.e., day 0), and after the end of molding (i.e., day 15), blood was taken and the mice were sacrificed, and then the ear thickness of the mice was immediately measured, and the measurement results are shown in fig. 1.
As shown in FIG. 1, Bifidobacterium infantis REGO can significantly reduce the thickness of the ears of mice with atopic dermatitis, and relieve the swelling degree of the ears of the mice. The above experimental results show that bifidobacterium infantis REGO has the effect of relieving the thickness and swelling degree of the ears of atopic dermatitis mice.
Example 4: effect of Bifidobacterium infantis on eosinophil infiltration in atopic dermatitis mice
30 healthy female C57BL/6 mice weighing 18-20g were randomly divided into 5 groups of 10 mice each, and 3 groups were: a blank group (control group), a model group administered with 2, 4-dinitrofluorobenzene (2, 4-dinitrofluorobenzene, DNFB), and a REGO group administered with Bifidobacterium infantis REGO, wherein the REGO group is a treatment group.
The experiment was carried out for four weeks: the first week is the adaptation period of the mice; beginning intragastric administration in the second week until the experiment is finished, and respectively performing intragastric administration on the Bifidobacterium infantis REGO bacterial liquid in the treatment groups by 0.2mL (the total amount of viable bacteria in single intragastric administration is 1 × 10) 9 Performing gavage at the dosage of CFU)/one time, wherein the blank group and the model group are not subjected to bacterial liquid intervention, and only the same amount of physiological saline is used as a control; the third week to the fourth week are modeling periods, the skin on the back of 5 groups of mice is depilated on the 1 st day of modeling, the area is about 2.5cm multiplied by 2.5cm, 50 mu L of DNFB solution with the concentration of 0.5% is used for coating the hair removal area on the back of the model group and the hair removal area on the back of the mice of the treatment group for skin damage sensitization and excitation, 20 mu L of DNFB solution with the concentration of 0.2% is used for coating the hair removal area on the back of the model group and the hair removal area on the back of the mice of the treatment group on the 5 th day, the 8 th day, the 11 th day and the 14 th day, and the hair removal area on the back of the mice of the blank group is only coated with the same amount of acetone/olive oil matrix solution as a control; all groups were free water and food intake.
After the molding is finished (i.e. day 15), blood is taken and the mice are sacrificed, and the serum total IgE level of the serum is measured by an enzyme-linked immunosorbent assay kit (the result is shown in figure 2).
As can be seen from fig. 2, bifidobacterium infantis REGO significantly reduced the serum total IgE level of mice compared to the model group, and was beneficial to suppress Th2 type immune response, thereby helping to alleviate the pathological inflammation of atopic dermatitis. The experiments show that the bifidobacterium infantis REGO can obviously reduce the total IgE level in the serum of mice and is beneficial to relieving the pathological inflammation of atopic dermatitis.
Example 5: effect of Bifidobacterium infantis on IL-4, IL-13 levels in skin tissues of atopic dermatitis mice
30 healthy female C57BL/6 mice weighing 18-20g were randomly divided into 5 groups of 10 mice each, and 3 groups were: a blank group (control group), a model group administered with 2, 4-dinitrofluorobenzene (2, 4-dinitrofluorobenzene, DNFB), and a REGO group administered with Bifidobacterium infantis REGO, wherein the REGO group is a treatment group.
The experiment was carried out for four weeks: the first week is the adaptation period of the mice; beginning intragastric administration in the second week until the experiment is finished, and respectively performing intragastric administration on the Bifidobacterium infantis REGO bacterial liquid in the treatment groups by 0.2mL (the total amount of viable bacteria in single intragastric administration is 1 × 10) 9 Performing gavage at the dosage of CFU)/one time, wherein the blank group and the model group are not subjected to bacterial liquid intervention, and only the same amount of physiological saline is used as a control; the third week to the fourth week are modeling periods, the skin on the back of 5 groups of mice is depilated on the 1 st day of modeling, the area is about 2.5cm multiplied by 2.5cm, 50 mu L of DNFB solution with the concentration of 0.5% is used for coating the hair removal area on the back of the model group and the hair removal area on the back of the mice of the treatment group for skin damage sensitization and excitation, 20 mu L of DNFB solution with the concentration of 0.2% is used for coating the hair removal area on the back of the model group and the hair removal area on the back of the mice of the treatment group on the 5 th day, the 8 th day, the 11 th day and the 14 th day, and the hair removal area on the back of the mice of the blank group is only coated with the same amount of acetone/olive oil matrix solution as a control; all groups were free water and food intake.
After the molding is finished (namely, day 15), blood is taken and the mice are sacrificed, then skin tissues of depilated areas on the backs of the mice are taken, and the levels of Th2 type immunoreaction cytokines IL-4 and IL-13 are measured by an enzyme-linked immunosorbent assay kit (the results are shown in figures 3-4).
As can be seen from fig. 3-4, bifidobacterium infantis REGO significantly reduced the levels of IL-4 and IL-13 in mouse skin tissues and significantly suppressed Th2 type immune response, compared to the model group, thereby contributing to the alleviation of pathological inflammatory conditions caused by Th2 type abnormal immune response. The experiments show that the bifidobacterium infantis REGO can obviously reduce the levels of cytokines IL-4 and IL-13 related to Th2 type immune response, and is helpful for relieving pathological inflammation states caused by Th2 type abnormal immune response.
Example 6: effect of Bifidobacterium infantis on Histamine levels in skin tissues of atopic dermatitis mice
30 healthy female C57BL/6 mice weighing 18-20g were randomly divided into 5 groups of 10 mice each, and 3 groups were: a blank group (control group), a model group administered with 2, 4-dinitrofluorobenzene (2, 4-dinitrofluorobenzene, DNFB), and a REGO group administered with Bifidobacterium infantis REGO, wherein the REGO group is a treatment group.
The experiment was carried out for four weeks: the first week is the adaptation period of the mice; beginning intragastric administration in the second week until the experiment is finished, and respectively intragastric administration of Bifidobacterium infantis REGO bacterial solution in the treatment groups by 0.2mL (the total amount of viable bacteria in single intragastric administration is 1 × 10) 9 Performing gavage at the dosage of CFU)/one time, wherein the blank group and the model group are not subjected to bacterial liquid intervention, and only the same amount of physiological saline is used as a control; the third week to the fourth week is a molding period, the skin on the back of 5 groups of mice is depilated on the 1 st day of molding, the area is about 2.5cm multiplied by 2.5cm, 50 microliter of DNFB solution with the concentration of 0.5% is smeared on the depilated areas on the back of the mice of the treatment group for skin damage sensitization and excitation, 20 microliter of DNFB solution with the concentration of 0.2% is smeared on the depilated areas on the back of the mice of the treatment group on the 5 th day, the 8 th day, the 11 th day and the 14 th day, and the depilated areas on the back of the mice of the blank group are smeared with the same amount of acetone/olive oil matrix solution as a control; all groups were free water and food intake.
After the molding is finished (namely day 15), blood is taken and the mice are sacrificed, then skin tissues of the depilated area on the back of the mice are taken, and inflammatory factors related to the degranulation condition of the mast cells are measured by an enzyme-linked immunosorbent assay kit: histamine (results are shown in figure 5).
As can be seen from fig. 5, bifidobacterium infantis REGO significantly reduced the level of histamine in skin tissues of mice compared to the model group, so that it can be concluded that bifidobacterium infantis REGO significantly reduced the degranulation of mast cells, prevented the release of histamine in skin damaged tissues, and alleviated the skin itching condition of mice. The above experiments show that bifidobacterium infantis REGO can significantly reduce the level of histamine in skin tissues and inhibit the degranulation condition of mast cells in the skin tissues, thereby relieving the pruritus of the skin of mice and preventing the further development of atopic dermatitis.
Example 7: preparation method of solid beverage containing Bifidobacterium infantis REGO
Inoculating bifidobacterium infantis REGO into a culture medium according to the inoculation amount accounting for 3% of the total mass of the culture medium, and culturing at 37 ℃ for 18 hours to obtain a culture solution; centrifuging the culture solution to obtain thalli; will be culturedCentrifuging the solution to obtain thalli; cleaning the bacteria for 3 times by using a phosphate buffer solution with the pH value of 7.2-7.4, and then re-suspending the bacteria by using a trehalose freeze-drying protective agent with the trehalose concentration of 100g/L (the mass ratio of the freeze-drying protective agent to the bacteria is 2:1) to obtain a re-suspension; freeze-drying the heavy suspension by adopting a vacuum freezing method to obtain bifidobacterium infantis REGO bacterial powder; wherein the culture medium comprises 87.7 percent of water, 10 percent of enzyme hydrolysis skim milk, 0.5 percent of glucose, 1.5 percent of tryptone and 0.3 percent of yeast extract solution by mass of the total culture medium; the pH of the medium was 6.8; will contain 1X 10 10 And (3) mixing the CFU bifidobacterium infantis REGO powder with maltodextrin, wherein the total mass of the powder and the maltodextrin is 1g, so as to obtain the solid beverage rich in the bifidobacterium infantis REGO. Taking 10g of the solid beverage containing the bifidobacterium infantis REGO, re-dissolving the solid beverage with physiological saline, fixing the volume to 20mL, and feeding each mouse with 0.2mL of stomach every day for three weeks, so that the symptom of atopic dermatitis of the mouse can be effectively relieved, and the solid beverage has excellent effect on preventing and/or treating the atopic dermatitis.
Example 8: fermented food containing bifidobacterium infantis REGO prepared by using the same
Selecting fresh vegetables or fruits, cleaning, and squeezing to obtain juice, wherein the juice comprises one or more of Chinese cabbage, white radish, cucumber, beet and yellow peach products as raw materials. Sterilizing the juiced raw materials at high temperature instantly, sterilizing at 140 deg.C for 2 s, immediately cooling to 37 deg.C, inoculating Bifidobacterium infantis REGO or microbial agent leaven containing the strain to make the concentration of Bifidobacterium infantis REGO reach 10 8 More than CFU/mL, and refrigerating and storing at the temperature of 4 ℃ to obtain the fruit and vegetable beverage containing the live bifidobacterium infantis REGO bacteria. The method comprises the step of producing fermented food by using bifidobacterium infantis REGO as a fermenting microorganism, wherein the fermented food comprises solid food, liquid food and semi-solid food. The fermented food comprises dairy products, bean products and fruit and vegetable products, wherein the dairy products comprise fermented dairy products, cream, cheese, milk-containing beverages and milk powder; the bean product comprises soybean milk and soybean milk powder; the fruit and vegetable products comprise Chinese cabbage, white radish, cucumber, beet and yellow peach products. The prepared fermented food is effective in relievingThe symptoms of atopic dermatitis in mice, has an excellent effect in preventing and/or treating atopic dermatitis.
The applicant states that the present invention is illustrated in detail by the above examples, but the present invention is not limited to the above detailed methods, i.e. it is not meant that the present invention must rely on the above detailed methods for its implementation. It should be understood by those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, and the addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
Sequence listing
<110> Zhenjiang beneficial bacteria engineering biology Co., Ltd
<120> Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and use thereof
<141> 2022-04-22
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1216
<212> DNA
<213> Bifidobacterium infantis REGO (Bifidobacterium infantis)
<400> 1
gggaattggg ggggtgctat acatgcagtc gaacgagttc tgattattga gcgtgggggg 60
tcttaccatg cagtcgaacg ggatccctgg cagcttgctg tcggggtgag agtggcgaac 120
gggtgagtaa tgcgtgacca acctgccctg tgcaccggaa tagctcctgg aaacgggtgg 180
taataccgga tgctccgctc catcgcatgg tggggtggga aatgcttttg cggcatggga 240
tggggtcgcg tcctatcagc ttgttggcgg ggtgatggcc caccaaggcg ttgacgggta 300
gccggcctga gagggtgacc ggccacattg ggactgagat acggcccaga ctcctacggg 360
aggcagcagt ggggaatatt gcacaatggg cgcaagcctg atgcagcgac gccgcgtgcg 420
ggatggaggc cttcgggttg taaaccgctt ttgttcaagg gcaaggcacg gtttcggccg 480
tgttgagtgg attgttcgaa taagcaccgg ctaactacgt gccagcagcc gcggtaatac 540
gtagggtgcg agcgttatcc ggatttattg ggcgtaaagg gctcgtaggc ggttcgtcgc 600
gtccggtgtg aaagtccatc gcctaacggt ggatctgcgc cgggtacggg cgggctggag 660
tgcggtaggg gagactggaa ttcccggtgt aacggtggaa tgtgtagata tcgggaagaa 720
caccaatggc gaaggcaggt ctctgggccg tcactgacgc tgaggagcga aagcgtgggg 780
agcgaacagg attagatacc ctggtagtcc acgccgtaaa cggtggatgc tggatgtggg 840
gccctttcca cgggtcccgt gtcggagcca acgcgttaag catcccgcct ggggagtacg 900
gccgcaaggc taaaactcaa agaaattgac gggggcccgc acaagcggcg gagcatgcgg 960
gattaattcg atgcaacgcg aaggaccctt acctggggct tgacatgtgc cggatcgccg 1020
tggagacacg gtttcccttc ggggccggtt cacaggtggt tgcatggtcg gtcgtcagct 1080
cgtgttcgtg agatgtttgg gtaagttccc gcacgacgca ccctcgccgc atgtttggca 1140
acggttgatg ccggaaacct catgtgggac cgcggggtca cctcggaagg gagggtggga 1200
atgaccgtca cgattc 1216
Claims (9)
1. A Bifidobacterium infantis characterized in that it is identified as Bifidobacterium infantis: (A), (B), (C)Bifidobacterium infantis) The strain is named as REGO and is preserved in China center for type culture Collection with the preservation date of 2021, 03 and 24 days and the preservation number of CCTCC No. M2021268.
2. Use of Bifidobacterium infantis according to claim 1 for the preparation of a medicament or food for the prophylaxis and/or treatment of atopic dermatitis.
3. The use according to claim 2, wherein the medicament or food product has a viable count of Bifidobacterium infantis of not less than 1 x 10 6 CFU/g or 1X 10 6 CFU/mL。
4. The use according to claim 2, wherein the food product is a health food; or the food comprises dairy products, bean products, meat products or fruit and vegetable products.
5. A composition comprising bifidobacterium infantis as claimed in claim 1.
6. Composition according to claim 5, characterized in that it comprises Bifidobacterium infantis as claimed in claim 1, a pharmaceutical carrier and/or a pharmaceutical excipient.
7. The composition of claim 5, wherein the composition comprises Bifidobacterium infantis as in claim 1 and a dietary supplement.
8. The composition according to claim 5, wherein the composition comprises a bacterial preparation obtained by drying a bacterial solution containing Bifidobacterium infantis according to claim 1.
9. Use of the composition according to claim 5 for the preparation of a medicament or food for the prevention and/or treatment of atopic dermatitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210433128.1A CN114908004A (en) | 2022-04-24 | 2022-04-24 | Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210433128.1A CN114908004A (en) | 2022-04-24 | 2022-04-24 | Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114908004A true CN114908004A (en) | 2022-08-16 |
Family
ID=82765401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210433128.1A Withdrawn CN114908004A (en) | 2022-04-24 | 2022-04-24 | Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114908004A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518080A (en) * | 2022-10-20 | 2022-12-27 | 微康益生菌(苏州)股份有限公司 | Application of bifidobacterium lactis BLA80 in improving and relieving anaphylactic reaction |
-
2022
- 2022-04-24 CN CN202210433128.1A patent/CN114908004A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115518080A (en) * | 2022-10-20 | 2022-12-27 | 微康益生菌(苏州)股份有限公司 | Application of bifidobacterium lactis BLA80 in improving and relieving anaphylactic reaction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
| CN109652349B (en) | Bifidobacterium longum capable of relieving atopic dermatitis and application thereof | |
| CN114317320B (en) | Bifidobacterium breve 207-1 and application thereof | |
| EP2481299B1 (en) | Bifidobacterium bifidum strains for application in gastrointestinal diseases | |
| EP3124031B1 (en) | Sleep quality improver | |
| EP2650002A1 (en) | Bifidobacterium cect 7765 and use thereof in the prevention and/or treatment of excess weight, obesity and related pathologies | |
| TWI759126B (en) | Anti-inflammation and treatment of inflammatory disorders with liquid culture of lactic acid bacteria strains | |
| EP2828375A1 (en) | Gaba-producing culturable bacteria derived from the human gastrointestinal tract | |
| KR102543494B1 (en) | Novel probiotics and use thereof | |
| JP2022140607A (en) | Compositions and methods of use of novel strains of lactobacillus fermentum | |
| WO2017047777A1 (en) | Serotonin deficiency amelioration agent for after stress-load release | |
| CN110484459B (en) | Lactobacillus plantarum and application thereof | |
| CN114908004A (en) | Bifidobacterium infantis capable of preventing and/or treating atopic dermatitis and application thereof | |
| CN117025489B (en) | Bifidobacterium animalis subspecies VB315 and application thereof | |
| CN114774315A (en) | Application of lactobacillus rhamnosus strain LRa05 in preparing immunity enhancing and/or eczema relieving product | |
| CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof | |
| CN110960562B (en) | Probiotic composition with anti-allergy effect | |
| CN114686405B (en) | Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| WO2008002484A2 (en) | Novel lactobacillus bulgaricus strain and compositions | |
| CN112546074B (en) | Bifidobacterium breve capable of inhibiting release of IL-23 and Th17 axis-related inflammatory factors and application thereof | |
| TWI642363B (en) | Qol improving or sustaining agent | |
| CN111700917B (en) | A product for preventing and/or treating atopic dermatitis | |
| CN114410533A (en) | Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis | |
| CN111296842B (en) | Probiotic composition with anti-allergy effect | |
| CN109674060B (en) | Probiotic dietary supplement with auxiliary function of relieving type II diabetes and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220816 |
|
| WW01 | Invention patent application withdrawn after publication |